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Abstract
Background: Bladder transitional cell carcinoma (BTCC) is the fourth most frequent neoplasia in men, clinically
characterized by high recurrent rates and poor prognosis. Availability of urinary tumor biomarkers represents a
convenient alternative for early detection and disease surveillance because of its direct contact with the tumor and
sample accessibility.
Results: We tested urine samples from healthy volunteers and patients with low malignant or aggressive BTCC to
identify potential biomarkers for early detection of BTCC by two-dimensional electrophoresis (2-DE) coupled with
mass spectrometry (MS) and bioinformatics analysis. We observed increased expression of five proteins, including
fibrinogen (Fb), lactate dehydrogenase B (LDHB), apolipoprotein-A1 (Apo-A1), clusterin (CLU) and haptoglobin (Hp),
which were increased in urine samples of patients with low malignant or aggressive bladder cancer. Further
analysis of urine samples of aggressive BTCC showed significant increase in Apo-A1 expression compared to low
malignant BTCC. Apo-A1 level was measured quantitatively using enzyme-linked immunosorbent assay (ELISA) and
was suggested to provide diagnostic utility to distinguish patients with bladder cancer from controls at 18.22 ng/
ml, and distinguish patients with low malignant BTCC from patients with aggressive BTCC in two-tie grading
system at 29.86 ng/ml respectively. Further validation assay showed that Apo-A1 could be used as a biomarker to
diagnosis BTCC with a sensitivity and specificity of 91.6% and 85.7% respectively, and classify BTCC in two-tie
grading system with a sensitivity and specificity of 83.7% and 89.7% respectively.
Conclusion: Taken together, our findings suggest Apo-A1 could be a potential biomarker related with early
diagnosis and classification in two-tie grading system for bladder cancer.
Background
Bladder cancer is one of the tumors associated with the
highest morbidity and mortality. It is the second most
common urological cancer, clinically characterized by
high recurrent rates and poor prognosis once tumors
invade the lamina propia [1]. Cystoscopy and cytology
are currently considered the ‘gold standards’ for the
identification and monitoring for recurrence or progres-
sion of bladder cancer. Frequent cystoscopies facilitate
the treatment of recurrences at an early stage, thereby
potentially slowing the progression of the disease to
muscle invasive disease. However, cystoscopy is an inva-
sive, time-consuming and expensive examination and is
not well-accepted for patients [2]. Urine cytology is a
highly specific, noninvasive adjunct to cystoscopy that is
quite sensitive in detecting high grade bladder cancers.
However, it has poor sensitivity in detecting low grade
disease, and its accuracy is dependent on the patholo-
gists’ experience [3]. Therefore, scientists are interested
in identifying reliable non-invasive biomarkers that
could be utilized in screening, leading to early detection
and/or in predicting the progression of superficial
tumors to invasive higher-stage lesions with high specifi-
city and sensitivity.
Proteomic patterns in body fluids present new oppor-
tunities for the development of novel, highly sensitive
diagnostic tools for early detection of cancer [4]. A
major goal in the field of clinical proteomics is to iden-
tify disease biomarkers in biological fluids that can be
measured relatively inexpensively for early diagnosis of
disease. Most of the focus thus far has been on
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directly exposed by bladder epithelium, it is the impor-
tant source of information for bladder cancers. Also,
urine can be collected non-invasively in large amounts,
which provides an attractive alternative to blood plasma
as a potential source of disease biomarkers for bladder
cancer. Two-dimensional electrophoresis (2-DE) has
been the mainstay of electrophoresis technology for a
decade and is the most widely used tool for separating
protein mixtures such as in cell and tissue extracts or
body fluids [6]. Mass spectrometry (MS) allows the ana-
lysis and identification of very small amounts of protein
isolated from the gel. In the past 10 years, 2-DE fol-
lowed by MS has been the primary technique for bio-
marker discovery in conventional proteomic analyses
[7,8]. Several proteins in urine are measured as markers
for bladder cancers as well as those in blood, such as
bladder tumor antigen [9], nuclear matrix proteins [10]
and fibrinogen degradation products [11].
A cornerstone in the investigation of bladder cancer is
the recognition of the two phenotypic tumors: low
malignant and aggressive BTCC [12,13], which sug-
gested two-tie grading system in BTCC [14,15]. The low
malignant BTCC, accounting for 70%-80% of the
urothelial carcinomas, presents as superficial, papillary
lesions which has a propensity to recur, but only infre-
quently progresses to muscle-invasive stage or metasta-
size. The pathological characteristic is low-grade/well-
differentiated neoplasms, previously classified as grade I-
II. If treated promptly, the 5-year survival rate of this
variant can approach 90%. The aggressive BTCC,
accounting for 20%-30%, presents as an invasive tumor
at diagnosis, and has a very high risk of progressing to
incurable distant metastases. Their pathological mor-
phology is the high-grade lesion that begins as dysplasia
or carcinoma in situ, and occasionally as high-grade
papillary carcinoma. Thus, BTCC appears to develop
and progress via two distinctive phenotypic pathways
with drastically different biological behavior and clinical
outcome, which strongly supported by genetic analyses
and clinical experimental evidence [16,17]. Early diagno-
sis and exact classification are two major challenges
facing bladder cancer investigations. Currently, the
molecular basis for these characteristics of these two
phenotypic tumors is still unknown and no effective bio-
markers found. Thus, we tend to identify new markers
for classification in two-tie grading system in order to
predicting both progression and treatment of BTCC.
The aim of this study was to identify the proteins
whose expression is elevated in urine samples of patients
with BTCC in comparison to that of healthy individuals
and to find out the potential relationship between differ-
entially expressed urinary proteins and the clinical diag-
nostic and classification of BTCC. Using the 2-DE
approach with subsequent MS, we identified five differ-
entially expressed proteins in urine samples from
patients with BTCC in the comparison to healthy indivi-
duals. Moreover, our data strongly suggested Apo-A1
could be a potential biomarker for BTCC early diagnosis
and clinical classification.
Results
Proteomics of urine samples from the healthy individuals
and bladder cancer patients
To determine the changes in the protein expression pat-
tern due to bladder cancer, 2-DE was performed on
urine samples from patients with low malignant or
aggressive BTCC, or healthy individuals as control. Pro-
tein spots were visualized using Coomassie Brilliant Blue
(CBB) G-250. 2-DE images obtained from urine samples
of healthy volunteers and patients with low malignant
BTCC and aggressive BTCC respectively showed 613,
640 and 624 spots representing differentially expressed
proteins (Figure 1). The majority of the spots located
between molecular weight 10 kDa to 97 kDa in the pI
range 4.5-7.0. 2-DE images obtained from the urine
samples of sixteen normal volunteers revealed almost
the same expression pattern of proteins. Several spots,
which were present in urine samples of patients with
bladder cancer, were not present in urine samples of
healthy individuals.
If the relative protein content of two matched spots
from every two groups (healthy individuals, patients
with low malignant or aggressive BTCC) is different
more than 10-fold, we considered it as a differentially
expressed protein spot. According to this principle, 18
spots were identified, of which spots 1-6 were detected
in the urine samples of healthy individuals; spots 7 and
8 were only present in the samples of BTCC patients;
spots 16 and 17 were detected in the urine samples of
patients with low malignant BTCC; spot 18 was only
present in the urine samples of patients with aggressive
BTCC.
Identification of differentially expressed proteins by mass
spectrometry
To further identify the proteins which differentially
expressed among neoplastic versus non-neoplastic urine
samples, relative protein spots were excised from CBB
stained gels and identified by MS. Identified proteins are
shown in Table 1, including protein name, accession
number in NCBI, molecular weight (MW), isoelectric
point (pI), MASCOT score, total ion score and location.
Identification numbers in Table 1 matched with those
associated to the 2-DE spots shown in Figure 1. In this
study, 18 spots were found to be differentially expressed
between urine samples of patients with bladder cancer
and controls in a statistically significant manner. MS
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represent five proteins (More than one spot revealed the
presence of the same protein). These five proteins
include fibrinogen (Fb), lactate dehydrogenase B
(LDHB), apolipoprotein-A1 (Apo-A1), clusterin (CLU)
and haptoglobin (Hp). Spots 7, 8 and 16 were identified
to be different chains of fibrinogen, both spots 10 and
11 represented Apo-A1.
Confirmation of protein expression by Western blot
To quantify the expression of these identified proteins,
pooled urine samples were further examined by Western
Figure 1 2-DE profiles of urine samples. Pooled urine samples from 24 healthy individuals (A), 24 patients with low malignant BTCC (B) and
16 patients with aggressive BTCC (C) were resolved on 2-DE gels. Protein spots were visualized using CBB. Spots with more than 10-fold
difference of two matched spots from two different groups were numbered. The red arrows labeled with numbers indicate the position of the
differentially expressed proteins.
Table 1 Differentially expressed proteins identified by MS after 2-DE
Spot No. Protein Name Accession Number (NCBI) MW(Da) pI MASCOT score Total Ion Score C.I. % Location
S7 fibrinogen gamma chain gi|119625323 37714 5.87 177 100 T1,T2
S8 fibrinogen beta chain gi|119625344 39711 6.95 137 100 T1,T2
S9 lactate dehydrogenase B gi|119616854 36615 5.71 104 99.9988 T1,T2
S10 Apo-A1 gi|490098 28061 5.27 235 100 T1,T2
S11 Apo-A1 gi|490098 28061 5.27 207 100 T1,T2
S12 Clusterin gi|42740907 52461 5.89 102 99.9565 T1,T2
S13 hp2-alpha gi|296653 41499 6.25 115 98.9869 T1,T2
S16 fibrinogen gamma chain gi|119625325 35480 6.07 100 100 T1
T1: the protein expression increased in urine samples from patients with low malignant BTCC;
T2: the protein expression increased in urine samples from patients with aggressive BTCC.
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single predominant band at the expected molecular
weights (Figure 2). Fb, LDHB, Apo-A1, CLU and Hp
w e r es h o w nt ob eo f3 7k D a ,3 7k D a ,2 8k D a ,5 2k D a ,
42 kDa, respectively. Fb, LDHB, Apo-A1 and CLU
showed increasing trend in urine samples of patients
with bladder cancer, compared with healthy control,
while Hp expression didn’t change significantly.
Impressively, Apo-A1 expression level enhanced signifi-
cantly in urine samples of patients with bladder cancer,
particularly in aggressive BTCC group. Compared to
healthy volunteers Apo-A1 expression was increased 5-
fold and 11-fold in the urine samples of low malignant
BTCC and aggressive BTCC respectively. Compared to
low malignant BTCC group, the expression of Apo-A1
was increased by 3-fold in 85% of urine samples of
aggressive BTCC.
Apo-A1 expression in a series of independent urine
samples
Human Apolipoprotein A1 (Apo-A1) is the major pro-
tein component of high-density lipoprotein (HDL) in
plasma [18,19]. Previous studies have reported the diag-
nostic value of Apo-A1 in early tumor detection in that
increased levels of Apo-A1 were found in a variety of
malignant tumors [20,21]. Giusti et al [20] reported that
Apo-A1 precursor was significant up-regulated suggest-
ing it could be a potential protein biomarker in the
diagnostic classification of thyroid cancer. In the present
study, the expression of Apo-A1 was increased in pooled
urine samples of malignant patients compared to
healthy individuals in Western blot. Therefore, Apo-A1
was further tested by 2-DE using a series of independent
urine samples from healthy individuals, patients with
bladder benign damages and those with low malignant
or aggressive bladder cancers. Given many biomarkers
could be less specific in the presence of benign geni-
tourinary conditions [22,23]; we added urine samples
of patients with bladder benign damages as control.
Apo-A1 was detected in all urines samples (n = 40) of
bladder cancers classified as low malignant and aggres-
sive BTCC in two-tie grading system. But the expression
in aggressive BTCC was apparently higher compared to
low malignant BTCC. Apo-A1 was also found in some
of urine samples of the patients with bladder benign
damages and healthy volunteers; however, the expres-
sion was significantly low compared to BTCC group and
there was no significant difference detected between
these two groups (Figure 3). The result was consistent
with findings by Western blot.
Figure 2 Western blot validation of the proteins identified by
2-DE coupled with MS. Fb, LDHB, Apo-A1, CLU and Hp expression
in pooled urine samples from healthy individuals, patients with low
malignant or aggressive BTCC were further detected by Western
blot. Equal protein amount (25 μg) from each group was loaded
onto 10% SDS-PAGE gels. Antibodies were accepted as detecting a
single predominant band at the expected molecular weights.
Figure 3 2-DE profiles of Apo-A1 expression on independent
series of urine samples. Independent urine samples from healthy
individuals, patients with bladder benign damages, patients with
low malignant or aggressive BTCC were resolved on 2-DE gels and
stained by sliver. Differentially expressed Apo-A1 was highlighted
with an open oval which was further identified by MALDI-TOF/TOF-
MS. Three representative gels (Sample I, II and III) of each group
were shown.
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and classification
Apo-A1 was further tested whether quantitative mea-
surement could be utilized as a diagnostic tool to distin-
guish patients with bladder cancer from the healthy
volunteers by ELISA. Once calibration curves were pro-
ven to be analytically optimal, Apo-A1 was measured in
72 urine samples by an ELISA according to the manu-
facturer’s protocol. The result showed significant
increased Apo-A1 expression in BTCC groups (P< 0.01,
Figure 4A). Considering sample categorization given by
urinary cystoscopy, ROC analyses rendered a diagnostic
accuracy of 0.928, measured by the area under the curve
(AUC, P < 0.01, 95% confidence interval (CI) 0.870-
0.986), at an 18.22 ng/ml cutoff (Figure 4B). Apo-A1
was also tested whether quantitative measurement could
be utilized as a diagnostic tool to differentiate patients
with low malignant BTCC and aggressive BTCC. Using
the cystoscopy as the gold standard for urinary sample
categorization, Receiver operating curve (ROC) analyses
rendered a classified accuracy of 0.875, measured by the
AUC (P < 0.01, 95% CI 0.758-0.992), at a 29.86 ng/ml
cutoff (Figure 4C).
Validation of Apo-A1 as a biomarker for BTCC diagnosis
and classification
To further validate Apo-A1 as a potential biomarker for
diagnosis and classification of bladder cancer, 156 urine
samples from healthy individuals or patients with urin-
ary system diseases were harvested randomly. Apo-A1
levels were measured by ELISA and a clinical diagnosis
and classification were made according to the optimal
cutoff values suggested by ROC curves in Figure 4B and
4C. Using the histopathological result as the gold
Figure 4 Apo-A1 as a biomarker for predicting and classifying BTCC. (A) Quantitative proteomic analysis of Apo-A1 in urine samples by
ELISA. *P < 0.01, Student’s t-test. (B) Urianry Apo-A1 distinguishes bladder cancer on independent series of urine samples of patients with BTCC
and controls. ROC curve of urinary Apo-A1 as a detection marker for bladder cancer was based on a series of 72 urine samples. Among these, 40
had cancer-positive. The optimal cutoff was 18.22 ng/ml, and the AUC obtained was 0.928 (95% CI 0.870-0.986). (C) Urinary Apo-A1 classifies with
a different series of urine samples of patients with low malignant or aggressive BTCC. ROC curve of urinary Apo-A1 as a detective classification
marker for BTCC was based on a series of 40 urinary specimens, which consists of 24 low malignant BTCC and 16 aggressive BTCC. The optimal
cutoff was 29.86 ng/ml, and the AUC obtained was 0.875 (95% CI 0.758-0.992).
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and specificity of 91.6% and 85.7% at 18.22 ng/ml cutoff
(Table 2A); also it can classify BTCC in two-tie grading
system with a sensitivity and specificity of 83.7% and
89.7% at 29.86 ng/ml cutoff (Table 2B).
Discussion
Bladder cancer is the second most common urological
tumors, clinically characterized by high recurrent rates
and poor prognosis [1]. Thus, there is a clear need to
identify new tumor specific biomarkers for early diagno-
sis and accurate classification of BTCC to make an
appropriate therapeutic plan for cancer patients. Urine
diagnostics for bladder cancer is an important diagnosis
for years. Urine is directly exposed by bladder epithe-
lium and is the important source of information for
bladder cancers and readily collected. Here, we have
performed urine proteomic analysis using 2-DE coupled
with mass spectrometry. This represents a promising
approach for the identification of tumor biomarkers
aiming at the detection of the presence of bladder can-
cer and definite classification. Several proteins were
found to be differentially expressed in a significant man-
ner in urine samples of patients with bladder cancer as
compared to controls, or between different classes or
stages, as confirmed by gold standard diagnostic meth-
ods. In this study, we selected 18 spots with 10-fold var-
iation between 3 groups for MS identification. Some
spots were not included into the analysis because the
MASCOT scores of those spots were below the cutoff
score preset in the database or were identified as
unnamed protein product. Totally, we identified 8 spots
which are belong to 5 proteins, including fibrinogen
(Fb), lactate dehydrogenase B (LDHB), apolipoprotein-
A1 (Apo-A1), clusterin (CLU) and haptoglobin (Hp).
These proteins were differentially expressed in a signifi-
cant manner in urine samples of patients with bladder
cancer as compared to controls. We also identified spe-
cific biomarkers for classifying bladder cancer in two-tie
grading system and found urinary measurement of Apo-
A1 expression on independent series of urine samples
served to distinguish not only patients with bladder can-
cer from controls, but also patients with low malignant
BTCC from aggressive BTCC with high diagnostic
accuracy.
One of the markers identified in this study, Apo-A1, is
the major protein component of high-density lipoprotein
(HDL) in plasma [19]. It is synthesized in the liver and
intestine as a prepro-protein. Apolipoprotein levels
reflect the difference in HDL protein concentration
observed among healthy controls but are also influenced
by other possible confounders such as age, alcohol
intake, hormone use, sex, race, body mass index, and
coronary artery disease. Apo-Al is well-known as a
negative marker of inflammation; its concentration
decreases more than 25% during inflammation. Apo-A1
has been shown to be a specific inhibitor of cytokine
production by monocytes and macrophages in response
to interaction with stimulated T cells. Apo-A1 is a con-
stitutive anti-inflammatory factor, and the decrease in
HDL-associated Apo-A1 level may be a signal of chronic
inflammation progression. It was shown that Apo-A1
concentration in blood is reduced in different types of
cancer [24,25]. Apo-A1 has been identified as a potential
biomarker of ovarian cancer, colorectal cancer, and pan-
creatic cancer by using MS. However, controversial
observations were also reported including up-regulation
of Apo-A1 in a variety of malignant tumors of ovarian,
liver, breast [20,21].
In this study, spots 10 and 11 were identified as Apo-
A1 in the 2-DE gels followed by MS. In pooled urine
samples analyzed, we found a significant gradient dif-
ference in the chemiluminescence signal detected by
Western blot for Apo-A1 between groups of healthy
individuals and patients with low malignant and
aggressive BTCC. So the question of the possible use
of Apo-A1 for diagnosis and classification of BTCC
needs to be further addressed. Considering the expres-
sion levels in pooled samples do not reflect the expres-
sion level in individual sample, Apo-A1 was further
analyzed by 2-DE using a series of independent urine
samples. Given many biomarkers could be less specific
in the presence of benign genitourinary conditions
[22,23], we added urine samples of patients with blad-
der benign damages as control. According to the pro-
tein density visualized using silver, Apo-A1 showed
very low expression in urine samples of healthy indivi-
duals and patients with bladder benign damages, while
significant increase in urine samples of patients with
bladder cancer, particularly in those diagnosed as
aggressive BTCC. These results further suggest that
Apo-A1 could be a potential biomarker for diagnosis
and classification of BTCC.
Table 2 Validation of Apo-A1 as biomarker for diagnosis
(A) and classification (B) of BTCC
A
Gold standard Apo-A1 expression
>18.22 ng/ml <18.22 ng/ml
BTCC (107) 98 9
Benign damage (49) 7 42
B
Gold standard Apo-A1 expression
>29.86 ng/ml <29.86 ng/ml
Aggressive BTCC (49) 41 8
Low Malignant BTCC (58) 6 52
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tive measurement could be utilized as a diagnostic tool
to distinguish patients with bladder cancer and controls
and classify bladder cancer. ELISA was performed and
the result showed there was no difference between
healthy individuals and patients with bladder benign
damages, while the difference between these two groups
and BTCC group was significant (P < 0.01), suggesting
Apo-A1 could be a potential biomarker to distinguish
BTCC patients from healthy individuals and patients
with bladder benign damages. Also, the difference
between low malignant and aggressive BTCC was signif-
icant (P < 0.01), suggesting Apo-A1 could be a potential
biomarker to classify BTCC in two-tie grading system.
Using the cystoscopy as the gold standard for urinary
sample categorization, ROC analyses rendered a diag-
nostic accuracy of 0.928 at an 18.22 ng/ml cutoff. Apo-
A1 was also tested whether quantitative measurement
could be utilized as a diagnostic tool to differentiate
patients with low malignant BTCC and aggressive
BTCC. Using the cystoscopy as the gold standard for
urinary sample categorization, ROC analyses rendered a
classified accuracy of 0.875 at a 29.86 ng/ml cutoff.
These results indicated that Apo-A1 was detectable in
t h eu r i n ea n ds u p p o r t e dt h er o l eo fA p o - A 1t ob ea
potential biomarker for diagnosis and classification of
bladder cancer. To further validate above findings, 156
urine samples from healthy individuals or patients with
urinary system diseases were randomly collected. Apo-
A1 level was tested by ELISA. Clinical diagnosis and
classification were made according to the cutoff values
suggested by ROC analyses. Using the histopathological
diagnosis after subsequent surgical interventions as the
gold standard, Apo-A1 can distinguish between bladder
cancer patients and controls with high sensitivity and
specificity, which suggests the potential diagnostic appli-
cation of urinary Apo-A1 for bladder cancer. Low malig-
nant and aggressive BTCC were reported to develop and
progress via two distinctive phenotypic pathways with
drastically different biological behavior and clinical out-
come, which determines that definite classification will
be very helpful to decide medical treatment and predict
the prognosis. The validation assay dealt with classifica-
tion of bladder cancer further showed Apo-A1 can dis-
tinguish between low malignant and aggressive BTCC
with high sensitivity and specificity. All of these findings
strongly suggest the potential diagnostic utility of urin-
ary Apo-A1.
Fibrinogen (fg), identified from three spots in our
study, has been demonstrated to be associated with
bladder malignancy and be a determinant in metastatic
potential [26]. Fibrinogen Degradation Products (FDP)
analysis in urine is rapid and the test is available clini-
cally [22]. Several studies have shown that FDP is more
sensitive than voided urine cytology for low grade
tumors. However, the use of FDP as a tumor marker
may be limited in that several studies have found FDP
to be less specific than urine cytology, especially in the
presence of benign genitourinary conditions [22,23].
LDHB, which was detected in BTCC urine samples of
BTCC, is reported to be correlated with tumor expan-
sion and invasion and patients with malignancies com-
bined with increased serum LD isoenzymes activity
usually have a poor prognosis [27]. LDHB could com-
paratively distinguish lung cancer from benign lung dis-
ease and healthy control and was correlated with the
clinical stage of lung cancer [28], but there is no evi-
dence to show LDHB has any connections with bladder
cancer.
Recent study showed that urine CLU were signifi-
cantly higher in individuals with bladder cancer with
sensitivity of 49% and specificity of 92% respectively and
suggested urine CLU could be a possible marker for
bladder cancer. Our results are consistent with this. In
our study, differentially expressed protein spot 12 was
identified as CLU which was detected greatly increased
in urine samples of patients with bladder cancer. More-
over, CLU was detected more strongly expressed in
invasive BTCC compared with the expression in superfi-
cial BTCC and the pathologic stage and tumor grade
showed close associations with CLU expression [29,30].
All these lines of evidence suggest that CLU might be
considered as a potential diagnostic and prognostic bio-
marker for bladder cancer using urine, serum and/or
molecular biology techniques. Over expression of Hp is
very common in tumor cases. More and more evidence
has showed that the levels of Hp in plasmas go up in
many malignant tumors, such as pancreatic cancer,
ovarian cancer and acute leukemia [31,32]. In our study,
Spot 13 was identified as Hp a2 chain and it was found
greatly increased in urine sample of patients with blad-
der cancer. Though maybe it does not belong to specific
protein in bladder cancer, it could become an important
check index for bladder cancer diagnosis and classifica-
tion and improve the sensitivity and specificity of early
diagnosis in lung cancer when combining with other
diagnostic indexes.
Conclusions
Taken together, our study indicates that the 2-DE pro-
teomic analysis of urinary proteins is feasible for the
diagnosis of bladder cancer as well as the classification
in two-tie grading system. As a result of this approach,
our study demonstrated that Apo-A1 protein levels in
urine could serve as a biomarker for bladder cancer.
Further, it can classify BTCC in two-tie grading system.
Moreover, our results confirmed the importance of pre-
viously identified proteins and highlight new proteins
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cal mechanisms of bladder cancer.
Methods
Urinary Samples and Patients
Urine samples were collected with informed consents at
the Department of Urology of the Second Hospital of
Tianjin Medical University, including 24 volunteers with
no evidence of disease and no history or evidence of
urological cancer as normal controls, 8 volunteers with
other chronic benign lesions in bladder, and 40 patients
with BTCC. The average age of these three groups was
61.71 ± 8.35, 63.38 ± 4.93, and 63.00 ± 9.22, respec-
tively. Patients were confirmed without resent PMH
(post medical history) and any symptom of kidney fail-
ure. The presence of bladder cancer was confirmed by
cystoscopy, together with histopathological information
after subsequent surgical interventions. Tumors were
graded according to the WHO criteria [33] and classi-
fied according to classification of two-tie grading system
[14,15]. The number of patients with low malignant
BTCC and aggressive BTCC was 24 and 16 respectively.
Detailed clinical information was provided in Table 3.
Urine samples were collected before the surgical opera-
tions and immediately centrifuged at 1500 × g for 5 min
at 4°C to remove cell debris and particulate matter. 1 ml
of supernatant was stored at -80°C for ELISA; the rest
was employed for 2-DE sample preparation processing
immediately. The detailed clinical information of
patients providing urinary samples for Apo-A1 valida-
tion assay is not shown.
Sample preparation for 2-DE
Urine supernatant mixed with ethanol at a ratio of 3:1.
The mixture was incubated at 4°C for 10 min. The pre-
cipitant was collected by centrifuging at 12,000 × g for 5
min at 4°C and washed twice using 25% ethanol. The
pellet was resuspended in solubilizing buffer which
contained 7 M urea, 2 M thiourea, 4% CHAPS, 0.2%
ampholytes, 65 mM DTT. The concentration of urinary
proteins was determined by using the RC DC protein
assay kits (Bio-Rad). Inorganic salts and any other inter-
fering components were removed by using 2D Clean-Up
Kit (Bio-Rad).
2-DE and stain
Urine samples were diluted in 350 μl rehydration buffer
containing 7 M urea, 2 M thiourea, and 4% CHAPS,
0.2% (v/v) ampholytes (pH 3-10), 65 mM DTT, 2 mM
tributylephosphine (TBP) and a trace of bromophenol
blue. Diluted samples were loaded onto IPG strips,
17 cm pH 4-7 L, for the first dimension. Strips were
covered with mineral oil and passively rehydrated over-
night. IEF was performed at voltage linearly increased
from 150 to 8000 V during the first 10 h, followed by
10,000 V for a total of 75,000 Vh. Before the second-
dimensional run, IPG strips were equilibrated with the
buffer containing 6 M urea, 2% SDS, 0.375 M Tris-HCl
pH 8.8, 20% glycerol, 2% DTT for 15 min and equili-
brated further with the same buffer additionally contain-
ing iodoacetamide (2.5%) instead of DTT for 15 min
within the strip tray. The IPG strips were then placed
onto a 12% polyacrylamide gel and covered with 0.5%
agarose gel. The second dimension was run at 30 mA
for 4.5 h. Polyacrylamide gels were stained with CBB G-
250 and/or silver according to the procedures described
previously [34]. Each sample was used in triplicates. The
resulting 2-DE images were analyzed using the PDQuest
software program.
Identification of Proteins by MALDI-TOF/TOF-MS
Significantly differed protein spots were excised and
destained with a solution of 25 mM ammonium bicar-
bonate and 50% ACN. The gels were then dried comple-
tely by centrifugal lyophilization. An in-gel digestion was
performed with 0.01 μg/μl trypsin (Promega) in 25 mM
ammonium bicarbonate for 15 h at 37°C. The superna-
tants were collected, and the tryptic peptides were
extracted from the gel sequentially with 5% TFA at 40°C
for 1 h and with a solution of 2.5% TFA and 50% ACN
at 30°C for 1 h. The extracts were pooled and dried
completely by centrifugal lyophilization.The peptide
mixtures were redissolved in 0.5% TFA, and 1 μlo ft h e
peptide solution was mixed with 1 μlo fm a t r i x( 4 -
hydroxy-a-cyanocinnamic acid in 30% CAN and 0.1%
TFA) before spotting on the target plate. MALDI-TOF/
TOF-MS analysis of the samples was carried on a mass
spectrometer 4700 (Applied Biosystems, Framingham,
MA) in a positive ion reflector mode. Following
MALDI-TOF/TOF, the instrument was switched to MS/
MS mode, and the five strongest peptides from the MS
scan were isolated and fragmented by collision-induced
dissociation with air. The ion acceleration voltage was
20 kV. The obtained peptide mass fingerprinting data
were further processed using the GPS Explorer software
(Applied Biosystems) that acts as an interphase between
t h eO r a c l ed a t a b a s ec o n t a i n i n gt h er a ws p e c t r aa n da
local copy of the MASCOT search engine. The Homo
sapiens subsets of the sequences in the Swiss-Prot and
NCBI nonredundant protein sequence databases were
utilized for MASCOT searches. The following search
parameters were used in all MASCOT searches: limited
protein molecular weight from 700-4000 Da; peptide
mass tolerance of ± 0.1 Da; tolerance of one missed
trypsin cleavages; a maximum error tolerance of ±
2.0 Da in the MS data and ± 0.6 Da in the MS/MS data;
protein hits with more than five significant matched
peptides with the distinct sequences. A mass accuracy
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between 42 and 100 (NCBI Database) were statistically
considered to estimate the confidence of protein
identifications.
Western blot
Total urinary protein of healthy volunteers and patients
with bladder cancer was determined by RC DC protein
assay kits using BSA as the standard (Bio-Rad) and
equal protein amount (25 μg) was loaded onto 10%
SDS-PAGE gels. Subsequently, the electrophoresed pro-
teins were transferred to a PVDF membrane (Bio-Rad).
After blocking, the membrane was incubated with pri-
mary antibodies (Fb, F4639; LDHB, WH0003945M1;
Apo-A1, WH0000335M1; CLU, WH0001191M1; Hp,
H6395; all from Sigma) for 2 h at room temperature.
Following washing, the membrane was exposed to the
secondary antibodies conjugated with horseradish
Table 3 Clinical information of patients providing urinary samples included for 2-DE analysis
No. Age Sex Grade Two-tie grading system No. Age Sex Condition
15 7F G 2 Ⅰ 41 56 M chronic inflammation of bladder
25 5M G 2 Ⅰ 42 57 F chronic inflammation of bladder
36 5M G 1 Ⅰ 43 66 M chronic inflammation of bladder
46 4M G 2 Ⅰ 44 65 F bladder atypia hyperplasy
56 9F G 2 Ⅰ 45 70 M bladder atypia hyperplasy
66 6M G 2 Ⅰ 46 61 M bladder atypia hyperplasy
76 7F G 2 Ⅰ 47 67 M bladder atypia hyperplasy
87 5F G 2 Ⅰ 48 65 M inverted papilloma of bladder
95 1M G 1 Ⅰ 49 50 F normal
10 69 F G1 Ⅰ 50 53 F normal
11 60 M G1 Ⅰ 51 56 F normal
12 62 M G1 Ⅰ 52 58 F normal
13 60 M G2 Ⅰ 53 70 M normal
14 61 M G2 Ⅰ 54 72 M normal
15 69 M G2 Ⅰ 55 61 M normal
16 67 F G1- G2 Ⅰ 56 67 M normal
17 61 M G2 Ⅰ 57 59 M normal
18 79 M G2 Ⅰ 58 73 M normal
19 61 M G1- G2 Ⅰ 59 75 M normal
20 59 F G2 Ⅰ 60 64 M normal
21 54 M G2 Ⅰ 61 58 M normal
22 48 M G2 Ⅰ 62 52 M normal
23 56 M G1- G2 Ⅰ 63 72 M normal
24 57 F G2 Ⅰ 64 51 M normal
25 71 F G2-G3 Ⅱ 65 50 M normal
26 80 F G2-G3 Ⅱ 66 57 F normal
27 76 M G3 Ⅱ 67 63 F normal
28 53 M G3 Ⅱ 68 65 F normal
29 52 M G3 Ⅱ 69 54 F normal
30 59 M G3 Ⅱ 70 58 F normal
31 69 M G3 Ⅱ 71 77 F normal
32 60 M G3 Ⅱ 72 66 M normal
33 58 M G3 Ⅱ
34 39 M G3 Ⅱ
35 80 M G3 Ⅱ
36 55 M G3 Ⅱ
37 68 M G3 Ⅱ
38 72 M G3 Ⅱ
39 77 M G3 Ⅱ
40 59 M G3 Ⅱ
Ⅰ: Low Malignant BTCC; Ⅱ: Aggressive BTCC.
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Page 9 of 11peroxidase for 30 min. The antigen-antibody complex
was detected by enhanced chemiluminescence using
ECL reagents (Thermo Fisher Scientific) and visualized
by autoradiography. The X-ray films were digitalized for
subsequent densitometric quantification of the bands
using the morphometric program Optimas ( Optimas
Corporation, Seattle, USA).
Enzyme linked immunosorbent assay (ELISA)
Soluble urinary Apo-A1 concentrations were measured
by ELISA using Quantikine Immunoassay Kits (ADL).
Urine samples were centrifuged for 5 min at 1500 rpm
and the supernatants were utilized for ELISA. ELISA
was performed according to the methods recommended
by the manufacturer. After the development of the col-
orimetric reaction, the OD at 450 nm was quantified by
an eight-channel spectrophotometer, and the OD read-
ings were converted to nanograms per milliliter (ng/ml)
on the basis of the standard curves obtained with Apo-
A1 standard preparation in assay. Each sample was
tested in duplicate. Apo-A1 concentrations were repre-
sented as mean ± SD.
Statistical Analysis
Urine samples (n = 72) were utilized to analyze the clin-
ical utility of Apo-A1 at discriminating patients with
bladder cancer from healthy individuals and discriminat-
ing patients with low malignant BTCC from aggressive
BTCC. Urine samples categorization was based on cytol-
ogy and cystoscopic observations, the latter being uti-
lized as the “gold standard”. Receiving operating curve
(ROC) analyses were used to define the most optimal
diagnostic cutoff as well as the diagnostic performance
given by AUC, estimating its 95% confidence interval at
optimal cutoffs. Statistical analyses were performed
using the SPSS statistical package (version 13.0).
Abbreviations
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